It is essential to note that JAK phosphorylates other substrates than STAT, notably in the nucleus, highlighting a more complex signaling pathway that must be taken into account to better target the oncogenic properties of JAK proteins with JAK inhibitors (JAKi), as these sometimes display limited efficacy in treating cancers. This evidence concerns the gene SOAT1 and cancer.